Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zoë Y.G.J. van Lierop"'
Autor:
B. Moraal, Joep Killestein, Hannah McConchie, James Twose, Vincent de Groot, Bernard M. J. Uitdehaag, Lodewijk R.J. De Ruiter, Giovanni Licitra, Zoë Y.G.J. van Lierop, Frederik Barkhof, Kim A. Meijer, Ka-Hoo Lam
Publikováno v:
European Journal of Neurology, 29(2), 522-534. Wiley-Blackwell
Lam, K-H, Twose, J, McConchie, H, Licitra, G, Meijer, K, de Ruiter, L, van Lierop, Z, Moraal, B, Barkhof, F, Uitdehaag, B, de Groot, V & Killestein, J 2022, ' Smartphone-derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis ', European Journal of Neurology, vol. 29, no. 2, pp. 522-534 . https://doi.org/10.1111/ene.15162
Lam, K-H, Twose, J, McConchie, H, Licitra, G, Meijer, K, de Ruiter, L, van Lierop, Z, Moraal, B, Barkhof, F, Uitdehaag, B, de Groot, V & Killestein, J 2022, ' Smartphone-derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis ', European Journal of Neurology, vol. 29, no. 2, pp. 522-534 . https://doi.org/10.1111/ene.15162
Background: To investigate smartphone keystroke dynamics (KD), derived from regular typing, on sensitivity to relevant change in disease activity, fatigue, and clinical disability in multiple sclerosis (MS). Methods: Preplanned interim analysis of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3959c635bc177e801d01d742052d1028
https://doi.org/10.1111/ene.15162
https://doi.org/10.1111/ene.15162
Autor:
Iris Dekker, B. Moraal, Joep Killestein, Claire Bridel, Zoë Y.G.J. van Lierop, Frederik Barkhof, Harry Twaalfhoven, Cyra E. Leurs, Charlotte E. Teunissen, Zoé L.E. van Kempen, Bernard M. J. Uitdehaag
Publikováno v:
Neurology, 97(19), e1898-e1905. Lippincott Williams and Wilkins
Bridel, C, Leurs, C E, van Lierop, Z Y G J, van Kempen, Z L E, Dekker, I, Twaalfhoven, H A M, Moraal, B, Barkhof, F, Uitdehaag, B M J, Killestein, J & Teunissen, C E 2021, ' Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis ', Neurology, vol. 97, no. 19, pp. e1898-e1905 . https://doi.org/10.1212/WNL.0000000000012752
Bridel, C, Leurs, C E, van Lierop, Z Y G J, van Kempen, Z L E, Dekker, I, Twaalfhoven, H A M, Moraal, B, Barkhof, F, Uitdehaag, B M J, Killestein, J & Teunissen, C E 2021, ' Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis ', Neurology, vol. 97, no. 19, pp. e1898-e1905 . https://doi.org/10.1212/WNL.0000000000012752
Background and ObjectivesTo investigate the potential of serum neurofilament light (NfL) to reflect or predict progression mostly independent of acute inflammatory disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) treate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d479e406ad94a17ae2d443c4704f2f12
https://research.vumc.nl/en/publications/5a27c66f-b692-4957-bd83-15c1142619bc
https://research.vumc.nl/en/publications/5a27c66f-b692-4957-bd83-15c1142619bc
Autor:
Joep Killestein, Zoë Y.G.J. van Lierop, Tom B. G. Olde Dubbelink, Wouter J. C. van Ballegoij, B. Moraal, Alyssa A. Toorop, Bob W. van Oosten, Brigit A. de Jong, Bernard M. J. Uitdehaag, Charlotte E. Teunissen, Eva M.M. Strijbis, Zoé L.E. van Kempen
Publikováno v:
Multiple Sclerosis Journal. SAGE Publications Ltd
van Lierop, Z Y GJ, Toorop, A A, van Ballegoij, W J C, Olde Dubbelink, T B G, Strijbis, E M M, de Jong, B A, van Oosten, B W, Moraal, B, Teunissen, C E, Uitdehaag, B M J, Killestein, J & Kempen, Z L E V 2021, ' Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic ', Multiple Sclerosis Journal . https://doi.org/10.1177/13524585211028833
van Lierop, Z Y GJ, Toorop, A A, van Ballegoij, W J C, Olde Dubbelink, T B G, Strijbis, E M M, de Jong, B A, van Oosten, B W, Moraal, B, Teunissen, C E, Uitdehaag, B M J, Killestein, J & Kempen, Z L E V 2021, ' Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic ', Multiple Sclerosis Journal . https://doi.org/10.1177/13524585211028833
In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a8b19ad61887f194476be2b01e91d5b
https://pubmed.ncbi.nlm.nih.gov/34240631
https://pubmed.ncbi.nlm.nih.gov/34240631
Autor:
Simon Rinaldi, Filip Eftimov, Zoë Y.G.J. van Lierop, Lorena Martín-Aguilar, Camiel Verhamme, Luis Querol, Charlotte E. Teunissen, Luuk Wieske, Joep Killestein, Marleen J. A. Koel-Simmelink, Janev Fehmi, Madhurima Chatterjee, Cinta Lleixà
Publikováno v:
Wieske, L, Martín-Aguilar, L, Fehmi, J, Lleixà, C, Koel-Simmelink, M J A, Chatterjee, M, van Lierop, Z, Killestein, J, Verhamme, C, Querol, L, Rinaldi, S, Teunissen, C E & Eftimov, F 2021, ' Serum Contactin-1 in CIDP: A Cross-Sectional Study ', Neurology(R) neuroimmunology & neuroinflammation, vol. 8, no. 5 . https://doi.org/10.1212/NXI.0000000000001040
Neurology(R) neuroimmunology & neuroinflammation, 8(5). Lippincott Williams and Wilkins
Neurology® neuroimmunology & neuroinflammation, 8(5). Lippincott Williams and Wilkins
Neurology-Neuroimmunology & Neuroinflammation
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Neurology(R) neuroimmunology & neuroinflammation, 8(5). Lippincott Williams and Wilkins
Neurology® neuroimmunology & neuroinflammation, 8(5). Lippincott Williams and Wilkins
Neurology-Neuroimmunology & Neuroinflammation
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
ObjectiveTo investigate whether serum levels of contactin-1, a paranodal protein, correlate with paranodal injury as seen in patients with CIDP with antibodies targeting the paranodal region.MethodsSerum contactin-1 levels were measured in 187 patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b41f67ace5257fda9af2cf30ba908650
https://research.vumc.nl/en/publications/a2176fef-081d-4961-90c6-067683a680e2
https://research.vumc.nl/en/publications/a2176fef-081d-4961-90c6-067683a680e2
Autor:
Zoë Y.G.J. van Lierop, Joep Killestein, B. Moraal, Djoeke Doesburg, Eva M.M. Strijbis, Ka Hoo Lam, Lodewijk R.J. De Ruiter, Bernard M. J. Uitdehaag, Floor C. Loonstra
Publikováno v:
Multiple Sclerosis and Related Disorders. Elsevier
Loonstra, F C, De Ruiter, L R J, Doesburg, D, Lam, K H, Van Lierop, Z Y G J, Moraal, B, Strijbis, E M M, Killestein, J & Uitdehaag, B M J 2021, ' Project Y : The search for clues explaining phenotype variability in MS ', Multiple Sclerosis and Related Disorders . https://doi.org/10.1016/j.msard.2021.103337
Loonstra, F C, De Ruiter, L R J, Doesburg, D, Lam, K H, Van Lierop, Z Y G J, Moraal, B, Strijbis, E M M, Killestein, J & Uitdehaag, B M J 2021, ' Project Y : The search for clues explaining phenotype variability in MS ', Multiple Sclerosis and Related Disorders . https://doi.org/10.1016/j.msard.2021.103337
Background To study phenotypic variability in MS patients, well-defined unbiased cohort studies are necessary. The most common and probably most important confounding factor when studying disease phenotype in MS is age. Objective To describe study de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::147c5506e1db46c6e69f370bbf3469ef
https://research.vumc.nl/en/publications/6153f068-e78e-448b-b262-4f0870d505ad
https://research.vumc.nl/en/publications/6153f068-e78e-448b-b262-4f0870d505ad
Autor:
Eva E.M. Strijbis, Brigit A. de Jong, Mike P. Wattjes, Joep Killestein, Axel Petzold, Charlotte E. Teunissen, Zoë Y.G.J. van Lierop, Frederik Barkhof, Zoé L.E. van Kempen, Alyssa A. Toorop
Publikováno v:
Toorop, A A, van Lierop, Z Y G, Strijbis, E E M, Teunissen, C E, Petzold, A, Wattjes, M P, Barkhof, F, de Jong, B A, van Kempen, Z L E & Killestein, J 2021, ' Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab ', Neurology neuroimmunology & neuroinflammation, vol. 8, no. 1 . https://doi.org/10.1212/NXI.0000000000000904
Neurology® Neuroimmunology & Neuroinflammation
article-version (Version of Record) 3
Neurology neuroimmunology & neuroinflammation, 8(1). Lippincott Williams and Wilkins
Neurology® Neuroimmunology & Neuroinflammation
article-version (Version of Record) 3
Neurology neuroimmunology & neuroinflammation, 8(1). Lippincott Williams and Wilkins
ObjectiveTo describe the disease course of carryover progressive multifocal leukoencephalopathy (PML) after switching from natalizumab to ocrelizumab in 2 patients with relapsing-remitting MS.MethodsTwo case reports with 1 year of follow-up and retro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf594124493be3142bcc7a70992aeeee
https://doi.org/10.1212/nxi.0000000000000904
https://doi.org/10.1212/nxi.0000000000000904